BioSpace
Episodes
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
05 Mar 2025
Contributed by Lukas
Donald Trump’s tariffs have headlined myriad news stories this week—including at BioSpace, where we reported Pfizer CEO Albert Bourla’s claim th...
A Conversation With Kevin Marks, CEO of Delphia
04 Mar 2025
Contributed by Lukas
On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Kevin ...
Money Meets Medicine: A Disruptor's Guide to Life Sciences Investment
27 Feb 2025
Contributed by Lukas
Miruna Sasu, CEO of COTA, has been labeled as a disrupter in the industry. In this discussion, she highlights the challenges of investing in the life ...
Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More
26 Feb 2025
Contributed by Lukas
There was a high point this week for employees riding the rollercoaster that is currently the FDA, as 300 recently fired employees are reportedly bein...
Examining Gene Therapies, Bispecific Antibodies and Other Novel Modalities
25 Feb 2025
Contributed by Lukas
At the 2025 National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to medicine—wil...
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom
19 Feb 2025
Contributed by Lukas
President Trump has been on a staff cutting rampage since taking office, and this weekend, the hammer came down on an undisclosed number of FDA employ...
A Conversation With Dannielle Appelhans, CEO of COUR
18 Feb 2025
Contributed by Lukas
On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Dannielle...
Navigating Patient Journeys with Tom Whitehead
13 Feb 2025
Contributed by Lukas
BioSpace’s Head of Insights Lori Ellis and Tom Whitehead, co-founder of the Emily Whitehead Foundation discuss the challenges navigated by cancer p...
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
12 Feb 2025
Contributed by Lukas
We saw more action on the M&A front this week as Novartisbought back its blood thinner abelacimab and the rest of Anthos Therapeutics for up to $3...
RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market
05 Feb 2025
Contributed by Lukas
U.S. political maneuverings are keeping biopharma on its toes. Tuesday, Robert F. Kennedy, Jr. passed a major hurdle as the Senate Finance Committee v...
The Patient's Perspective with Tom Whitehead
30 Jan 2025
Contributed by Lukas
BioSpace's Head of Insights Lori Ellis and Tom Whitehead sit down and discuss cell and gene therapies from the perspectives of patients. What do c...
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
29 Jan 2025
Contributed by Lukas
In the week since Donald Trump took office, he’s caused quite the stir with healthcare-centered moves that include ordering the Department of Health...
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
22 Jan 2025
Contributed by Lukas
Donald Trump was sworn in as the 47th president of the United States on Monday, bringing with him a host of healthcare nominees and potential changes ...
Bonus: Q4 2024 Job Market Update
21 Jan 2025
Contributed by Lukas
In this bonus episode, BioSpace's vice president of marketing Chantal Dresner and careers editor Angela Gabriel take a look at Q4 job market perfo...
A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025
16 Jan 2025
Contributed by Lukas
In this episode of Denatured, Dr. Peter Marks M.D., PhD. gives his thoughts on the future of cell and gene therapies. He speaks candidly about opportu...
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
15 Jan 2025
Contributed by Lukas
The J.P. Morgan Healthcare Conference kicked off Monday with a flood of high-value deals, reinvigorating sentiment across the biopharma industry. John...
A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)
10 Jan 2025
Contributed by Lukas
TEASER: This episode is little sneak peak into upcoming podcasts as well as topics that will be discussed at the 2025 GenScript Biotech Global Forum o...
NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch
08 Jan 2025
Contributed by Lukas
Happy New Year! BioSpace released our NextGen: Class of 2025 this week, highlighting 25 biopharma startups to watch this year. The companies on this l...
Trials and Capital: Women’s Health and APAC's Healthcare Revolution
02 Jan 2025
Contributed by Lukas
This conversation focused on a few remaining topics discussed at length at Jefferies late last year, with the same topics anticipated to make an appea...
Analysis vs Beliefs, CEO Challenges, GLP-1 Investments
19 Dec 2024
Contributed by Lukas
2025 is set to change the industry. The new administration is poised to challenge many existing processes. The question is whether they will be based ...
Biopharma’s Manufacturing Push and Other 2024 Trends
18 Dec 2024
Contributed by Lukas
Note: BioSpace is taking a break for the holidays. The next episode of The Weekly will air Jan. 8, 2025. Happy New Year! Novo dominated headlines over...
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
11 Dec 2024
Contributed by Lukas
This week, GSK and Gilead and Arcellx presented key data at the American Society of Hematology (ASH) annual meeting as they vie for a competitive adva...
Previous Investment Patterns Set to Repeat in 2025
05 Dec 2024
Contributed by Lukas
“Cautious optimism” is circling once again as the industry approaches 2025. However, many companies are treading water, barely holding on as the m...
Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More
04 Dec 2024
Contributed by Lukas
It’s officially holiday shopping season, and biopharma is getting into the spirit. Novartis expanded its presence in Huntington’s, paying up to $2...
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
27 Nov 2024
Contributed by Lukas
Biopharma had its collective deal-making hat on heading into the Thanksgiving holiday, with Roche buying Poseida for up to $1.5 billion, and Sarepta a...
51%: The Untapped Market
21 Nov 2024
Contributed by Lukas
Women represent 51% of the population; not investing is a poor investment strategy. Incorporating women into leadership positions, into board rooms, i...
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
20 Nov 2024
Contributed by Lukas
President-elect Donald Trump announced last week that he would nominate prominent anti-vaxxer Robert F. Kennedy Jr. to lead the HHS. While this news c...
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
13 Nov 2024
Contributed by Lukas
Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage trials. Acquired by AbbVie i...
Investing in AI: Benefits, Regulatory Challenges
07 Nov 2024
Contributed by Lukas
No discussion regarding the future is complete unless AI is incorporated. In this episode, Konstantina Katcheves of Teva Pharmaceuticals and Sanskrit...
Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More
06 Nov 2024
Contributed by Lukas
Last week, Eli Lilly suffered a rare third-quarter earnings miss as diabetes and obesity drugs Mounjaro and Zepbound fell short of Wall Street expecta...
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
30 Oct 2024
Contributed by Lukas
Earnings heat up as Pfizer got a much-needed Q3 beat amidst criticism from activist investor Starboard Value. Novartis and Sanofi are among others tha...
Steady But Slow: Future Outlook for Investment
24 Oct 2024
Contributed by Lukas
In this episode, we’re talking money. The guests in this discussion recognize that the economic climate has been different (and more chaotic) in las...
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
23 Oct 2024
Contributed by Lukas
Last week, Gilead withdrew Trodelvy in bladder cancer after the antibody-drug conjugate failed to meet the primary endpoint in a confirmatory study. T...
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
16 Oct 2024
Contributed by Lukas
It’s that time again: earnings season. Q3 calls started out with a bit of a snore from J&J, which did beat analyst expectations but announced no...
How AI Could Ease Tension in Clinical Trials
10 Oct 2024
Contributed by Lukas
Designating something "safe" in this industry means acceptable risk. AI can help us improve acceptable risks if it is used appropriately. However, ind...
BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More
09 Oct 2024
Contributed by Lukas
The cell and gene therapy sector may be on the road to recovery after being met with investment headwinds following the highs seen during the pandemic...
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
02 Oct 2024
Contributed by Lukas
Bristol Myers Squibb notched one of this year’s biggest approvals as the FDA greenlit Cobenfy, formerly KarXT, as the first novel treatment for ...
AI Return on Investment: Just Because We Can, Should We?
26 Sep 2024
Contributed by Lukas
Globalization, return on investment, diverse data sets undiscovered: this episode continues the exploration of AI. As we see the industry level out AI...
Novo Grilled By Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval
25 Sep 2024
Contributed by Lukas
Novo Nordisk CEO Lars Fruergaard Jørgensen testified Tuesday in front of Sen. Bernie Sanders’ Senate health committee regarding the prices of Ozemp...
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024
18 Sep 2024
Contributed by Lukas
After their groundbreaking approval last year, infusions of Vertex and CRISPR Therapeutics’ and bluebird bio’s sickle cell gene therapies have beg...
AI Promises: Funding Data Literacy and Reality First
12 Sep 2024
Contributed by Lukas
As 2024 closes, it is only right to discuss where we are when it comes to AI and where we will be in the future. As technology continues to evolve an...
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
11 Sep 2024
Contributed by Lukas
Summit Therapeutics made headlines this weekend at the 2024 World Conference on Lung Cancer, revealing that its bispecific antibody outperformed Keytr...
Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases
04 Sep 2024
Contributed by Lukas
Eli Lilly shook up the weight loss market again last week, announcing plans to sell single-dose vials of its blockbuster GLP-1 drug Zepbound directly ...
Future-Proofing: Inclusive and Protective Patient Strategies
29 Aug 2024
Contributed by Lukas
As the legal landscape continues to evolve, the uncertainty surrounding diversity, equity and inclusion (DEI) initiatives increases though the life sc...
A Tough Ending, New Beginnings and China-U.S. Biopharma Relations
28 Aug 2024
Contributed by Lukas
Gene editing startup Tome Biosciences is laying off nearly its entire workforce, as biopharma companies continue to face challenges in the current mar...
New IRA Drug Prices, Lots of Layoffs, Moderna’s Vaccine Opportunity
21 Aug 2024
Contributed by Lukas
With the Democratic National Convention underway, the Biden Administration’s announcing the first 10 drug prices negotiated under the under the Infl...
Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations
15 Aug 2024
Contributed by Lukas
In the second part of the discussion, our guests address clinical trial design which if done without careful consideration of the patient population c...
Lykos Rejection, Pfizer’s RSV Win, Lilly Vs. Novo and More
14 Aug 2024
Contributed by Lukas
In one of the year’s most highly anticipated decisions, the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disor...
Pharma Campaign Contributions, Vaccine Hiccups and Lykos’ Moment of Truth
07 Aug 2024
Contributed by Lukas
This week, Kamala Harris selected Minnesota Governor Tim Walz as her running mate. In July, Harris’ campaign netted a whopping $310 million—so whe...
The Political Shape of the Future Clinical Trial Space
01 Aug 2024
Contributed by Lukas
The 2023 New Benchmarks on Demographic Disparities in Pivotal Trials study indicates that as Black representation increases, clinical trial enrollment...
2 Earnings Bonanza, M&A Accelerates and Alzheimer’s Data
31 Jul 2024
Contributed by Lukas
Second-quarter earnings season continues with Big Pharma beating Wall Street expectations, the author of an encrypted email sent to BioSpace has a pro...
Layoffs Persist, GLP-1s Launch for Weight Loss in China
24 Jul 2024
Contributed by Lukas
While the biopharma industry has seen glimmers of economic optimism, there were still more than 14,000 employees laid off in the first half of 2024. A...
Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?
18 Jul 2024
Contributed by Lukas
This is the third episode of Denatured's discussion on diversity, equity and inclusion (DE&I). AI represents unlimited opportunities to increa...
Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure
17 Jul 2024
Contributed by Lukas
Pfizer stole the show late last week with the announcement that it will move forward with its oral GLP-1 analog danuglipron. While Pfizer may hope to ...
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
10 Jul 2024
Contributed by Lukas
After securing approval last week for Alzheimer’s drug Kisunla, Eli Lilly was back in the news Monday with the $3.2 billion acquisition of immunolog...
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
03 Jul 2024
Contributed by Lukas
The biggest news of the week was the FDA approval of Eli Lilly’s Kisunla (donanemab) on Tuesday. While not unexpected, it was one of the year’s ...
DE&I: Understanding That We Don’t Understand at Molecular Level
02 Jul 2024
Contributed by Lukas
This is the second episode of Denatured's discussion on diversity, equity and inclusion (DE&I). Data is the essential piece for both science a...
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights
26 Jun 2024
Contributed by Lukas
The biggest news of the last week was easily the expanded approval of Sarepta’s Duchenne muscular dystrophy gene therapy, Elevidys. CBER Director Pe...
BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap
20 Jun 2024
Contributed by Lukas
BioSpace's Lori Ellis and Chantal Dresner are bringing live updates from #DIA2024 in San Diego this week where we've been a...
Challenging Research Models to Improve Health Equity
20 Jun 2024
Contributed by Lukas
Diversity, equity and inclusion (DEI) continues to be a challenge for drug and medical device developers. While there has been some improvement in cli...
BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More
19 Jun 2024
Contributed by Lukas
We’re off to a rocky start this week on the clinical side, with some safety issues. BioNTech and MediLink’s ADC was placed on partial hold after m...
BioSpace at #DIA2024: Convergence and Collaboration
17 Jun 2024
Contributed by Lukas
BioSpace's Lori Ellis and Chantal Dresner are bringing live updates from #DIA2024 in San Diego this week where the first day kicked off with an in...
Donanemab’s Promise, BIO Wrap and Mass Layoffs
12 Jun 2024
Contributed by Lukas
The big news of this week so far was Monday’s FDA advisory committee for Eli Lilly’s Alzheimer’s drug donanemab, where the vote was unanimous in...
BioSpace x DIA: Robust Integrated Regulatory Strategies
06 Jun 2024
Contributed by Lukas
How do we ensure strategic vision and thoughtful implementation when pursuing new opportunities in science and technology? Our guests discuss challeng...
The ABCs of Biopharma This Week: ASCO, BIO and Cancer
05 Jun 2024
Contributed by Lukas
Conference season kicked into high gear this week with the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and the BIO Internat...
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion
30 May 2024
Contributed by Lukas
Regulators suggest developers engage in discussions early, however those conversations cannot take place unless developers are sure of the asset's...
AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO
28 May 2024
Contributed by Lukas
At its Investor Day 2024 event last week, AstraZeneca announced plans to reach $80 billion in total revenue by 2030—up from $45.8 billion in 2023—...
BioSpace x DIA: Navigating the Emergence of CGT Combination Products
23 May 2024
Contributed by Lukas
With every new advancement in either science or technology there is increased excitement as we see the potential. Cell and gene therapies (CGT) as com...
Bayer’s New Strategy, Novo Vs. Lilly and Psychedelics
22 May 2024
Contributed by Lukas
Bayer’s recent layoffs of 1,500 mark a step toward CEO Bill Anderson’s stated goal of removing managerial layers at the company—“fewer bosses,...
Bayer Layoffs, a Big Alzheimer’s Deal and ASGCT Wrap
15 May 2024
Contributed by Lukas
Bayer made news this week announcing 1,500 layoffs as part of an effort to save €500 million ($540 million) in 2024 and €2 billion ($2.16 billion)...
Women's Health: Where Politics and Science Meet
09 May 2024
Contributed by Lukas
12 billion dollars: one of the boldest women’s health research moves an administration has made for women’s health research. On a global scale, th...
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
08 May 2024
Contributed by Lukas
In this edition of The Weekly, Managing Editor Jef Akst and News Editor Greg Slabodkin share their insights from the American Society of Gene & Ce...
BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy
03 May 2024
Contributed by Lukas
In this special edition of The Weekly, we discuss the much-anticipated annual meeting of the American Society of Gene & Cell Therapy in Baltimore....
The IRA, BMS’ Big Cuts, First WHIM Approval
01 May 2024
Contributed by Lukas
J&J and BMS’ challenges to Medicare drug price negotiations shut down in federal court less than a week after BMS announced it was laying off mo...
Where Do We Go From Here? The Future of Women's Health
25 Apr 2024
Contributed by Lukas
The potential impacts on clinical trial outcomes warrant a discussion surrounding the current definition of women’s health. In the second episode o...
Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player
24 Apr 2024
Contributed by Lukas
Sanofi will cut an undisclosed number of jobs as it revamps its U.S. vaccines commercial operations, as well as 99 employees from its Belgian sites—...
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages
17 Apr 2024
Contributed by Lukas
The past two weeks have seen Amylyx lose its only marketed product but receive numerous accolades for its decision to voluntarily withdraw Relyvrio a...
It's a Design Problem: Women and Clinical Trials
11 Apr 2024
Contributed by Lukas
Last month, President Biden signed an Executive Order on Advancing Women’s Health Research and Innovation, signalling the significance of women'...
Alphabet Soup: AACR and ACC Dominate Headlines This Week
10 Apr 2024
Contributed by Lukas
Conference season is in full swing, with the American Association for Cancer Research and American College of Cardiology concurrently holding their an...
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo
03 Apr 2024
Contributed by Lukas
WuXi AppTec was once again in the news this week, with speculation that the China-based biotech allegedly handed a U.S. client’s intellectual proper...
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?
28 Mar 2024
Contributed by Lukas
The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% o...
Bayer’s sweeping executive cuts, Wegovy’s expanding reach
27 Mar 2024
Contributed by Lukas
It was another busy week! Bayer reduced its executive suite from 14 to 8 as part of a major restructuring. Meanwhile, the government announced it will...
Money talk: Salary trends and raises
21 Mar 2024
Contributed by Lukas
This week, we're talking money! Following the release of BioSpace's 2024 Salary Report, we discuss salary trends and how they are impacting th...
Historic approval for MASH, CAR-Ts in the spotlight
20 Mar 2024
Contributed by Lukas
Phew, what a week! One of the most anticipated FDA decisions of the year dropped last week when the regulator approved Madrigal’s Rezdiffra as the f...
The unintended consequences of small molecules
14 Mar 2024
Contributed by Lukas
Continuing on from our previous episode "The gap is where the pain is", this episode focuses on a healthy discussion regarding the IRA, part...
The skinny on weight loss, donanemab and the State of the Union
13 Mar 2024
Contributed by Lukas
The weight loss market is the gift that keeps on giving—at least for Novo Nordisk—as Wegovy continues to demonstrate its prowess with label expans...
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
06 Mar 2024
Contributed by Lukas
These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer's strategic prioriti...
The gap is where the pain is: Drug pricing and patient costs
29 Feb 2024
Contributed by Lukas
When it comes to drug pricing, there have been (and are) bad actors in the industry, but the conversation usually ends there. Five KOLs from different...
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars
28 Feb 2024
Contributed by Lukas
This week Lori, Greg and Tyler discuss AbbVie: how longtime CEO Richard Gonzalez navigated Humira's LOE, his victorious retirement announcement, a...
Iovance wins with Amtagvi and the ADC train chugs on
21 Feb 2024
Contributed by Lukas
This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therap...
Eyes on the prize: Novo buys Catalent
14 Feb 2024
Contributed by Lukas
This week, Greg, Heather and Tyler discuss reaction to Novo Nordisk's purchase of Catalent and speculate on what that means for existing manufactu...
Balancing act: Patient access and innovation
07 Feb 2024
Contributed by Lukas
This week Lori, Greg and Tyler discuss drug pricing reforms. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare pri...
Keep calm and CAR-T on?
31 Jan 2024
Contributed by Lukas
Almost 30,000 patients have now been treated with CAR-T cell therapies since it was the first approval in 2017. In November 2023, the FDA launched a p...
What can biopharma expect from the job market?
25 Jan 2024
Contributed by Lukas
Following a challenging year of layoffs and limited funding, Chantal Dresner, VP of Marketing at BioSpace, discusses the findings of our most recent E...
Grab an umbrella, it's raining IPOs!
24 Jan 2024
Contributed by Lukas
The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announce...
Optimistic, but for how long? Our big takeaways from #JPM2024
17 Jan 2024
Contributed by Lukas
The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco. There was an air of hope and o...
On the ground at #JPM2024 - Day 3 highlights
10 Jan 2024
Contributed by Lukas
We're still in San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day three: disruptive...
On the ground at #JPM2024 - Day 2 highlights
10 Jan 2024
Contributed by Lukas
Once again we're recording from San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day ...
On the ground at #JPM2024 - Day 1 highlights
08 Jan 2024
Contributed by Lukas
Hello from San Francisco! BioSpace is reporting from #JPM2024 bringing you key takeaways and highlights from day one. Join Lori, Greg and Tyler as the...
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
04 Jan 2024
Contributed by Lukas
The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become mo...